Phakic IOL counters LASIK slowdown

Article

STAAR Surgical's Visian implantable collamer lens (ICL) & toric ICL (TICL) will allow surgeons to differentiate themselves in the slowing LASIK marketplace, according to the firm's president of international operations, David Bailey.

STAAR Surgical’s Visian implantable collamer lens (ICL) & toric ICL (TICL) will allow surgeons to differentiate themselves in the slowing LASIK marketplace, according to the firm’s president of international operations, David Bailey.

Mark Rosenberg, CEO of the Barnet Dulaney Perkins eye centre in Phoenix, Arizona, US, agrees and has seen strong growth in the lens-based sector. But, before this can be achieved, he says practices need to work to overcome the barriers to ICL uptake amongst patients. He says clinics must present ICLs at the beginning of the consultation process, rather than only where LASIK is not an option. Rosenberg says doctors need to shift the way they think, embracing the broader concept of vision correction rather than only LASIK.

“The only question for surgeons is, are you going to be left off the train and wind up giving up on refractive surgery, or are you going to move on?”

 

To read OTE's full news coverage of the XXVI congress of the European Society of Cataract & Refractive Surgery, please click here.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
© 2024 MJH Life Sciences

All rights reserved.